Merrill keeps Vertex at neutral

Vertex Pharmaceuticals Inc. was kept at a neutral rating by Merrill Lynch analyst Hari Sambasivam. Vertex will report on its fourth-quarter 2005 next week. Merrill's estimates for the quarter include total revenues of $54.6 million, including royalties of $9.6 million from Agenerase/Lexiva (based on sales of $55 million). The analyst's pro forma earnings-per-share estimate for the quarter is $0.25, essentially in line with consensus of $0.23. Shares of the Cambridge, Mass., biotechnology company were up 33 cents, or 0.92%, at $36.05 on volume of 1,099,153 shares versus the three-month running average of 1,368,570 shares. (Nasdaq: VRTX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.